We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Deucravacitinib: is there still a place or a need for a new oral agent?
- Authors
Sampogna, Francesca; Piaserico, Stefano
- Abstract
Deucravacitinib is an oral medication that has been shown to be effective and well-tolerated in patients with psoriasis. A recent study found that the drug continued to be safe and effective in the long-term, with the majority of adverse events being mild or moderate in severity. While biological treatments have shown great efficacy in managing psoriasis, oral medications still have a role to play, as they are easy to administer and avoid the issues associated with injections. However, currently available oral drugs have limitations in terms of efficacy and safety. Deucravacitinib, with its novel mechanism of action, appears to address these concerns and may provide a reliable and sustainable treatment option for psoriasis. Further research and clinical trials are needed to confirm these findings.
- Subjects
CLINICAL trials
- Publication
British Journal of Dermatology, 2024, Vol 190, Issue 5, p610
- ISSN
0007-0963
- Publication type
Article
- DOI
10.1093/bjd/ljae087